Viking Therapeutics, Inc. (VKTX)

NASDAQ: VKTX · Delayed Price · USD
2.23
-0.17 (-7.08%)
At close: May 18, 2022 4:00 PM
2.24
0.01 (0.45%)
Pre-market:May 19, 2022 7:16 AM EDT
Market Cap172.54M
Revenue (ttm)n/a
Net Income (ttm)-57.08M
Shares Out77.37M
EPS (ttm)-0.73
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume783,313
Open2.38
Previous Close2.40
Day's Range2.22 - 2.38
52-Week Range2.15 - 7.20
Beta1.66
AnalystsBuy
Price Target17.91 (+703.1%)
Earnings DateApr 27, 2022

About VKTX

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Pha...

IndustryBiotechnology
IPO DateApr 29, 2015
CEOBrian Lian
Employees17
Stock ExchangeNASDAQ
Ticker SymbolVKTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for VKTX stock is "Buy." The 12-month stock price forecast is 17.91, which is an increase of 703.14% from the latest price.

Price Target
$17.91
(703.14% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Viking Therapeutics to Present at H.C. Wainwright Global Investment Conference

SAN DIEGO , May 16, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and e...

2 days ago - PRNewsWire

Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH Expected in 2H22    Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 O...

3 weeks ago - PRNewsWire

Viking Therapeutics to Report Financial Results for First Quarter 2022 on April 27, 2022

Conference Call Scheduled for Wednesday, April 27 at 4:30 p.m. Eastern Time SAN DIEGO , April 20, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceut...

4 weeks ago - PRNewsWire

Viking Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

SAN DIEGO , April 6, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...

1 month ago - PRNewsWire

Viking Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO , March 8, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...

2 months ago - PRNewsWire

3 Biotech Stocks That Are too Cheap to Ignore

Our Motley Fool roundtable likes Intercept Pharma, Viking Therapeutics, and Vir Bio.

Other symbols:ICPTVIR
3 months ago - The Motley Fool

Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 9, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endo...

3 months ago - PRNewsWire

Viking Therapeutics to Present at SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO, Feb. 7, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and en...

3 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX

New York, New York--(Newsfile Corp. - February 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such inves...

3 months ago - Newsfile Corp

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2021 on February 9, 2022

SAN DIEGO, Feb. 2, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and en...

3 months ago - PRNewsWire

Viking (VKTX) Study on X-ALD Put on Clinical Hold by the FDA

Viking (VKTX) phase Ib study on VK0214 in patients with X-ALD put on hold by the FDA.

3 months ago - Zacks Investment Research

Why Viking Therapeutics Stock Got Mashed on Monday

The clinical trial has been halted by the FDA for now, pending the submittal of a preclinical study.

3 months ago - The Motley Fool

Viking Therapeutics' Early Stage Trial On FDA Hold In Rare Metabolic Disorder

The FDA has placed a clinical hold on Viking Therapeutics Inc's (NASDAQ: VKTX) Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD).  The FDA has requested an additional precl...

3 months ago - Benzinga

Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD

SAN DIEGO , Jan. 24, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and en...

3 months ago - PRNewsWire

Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, Company's Lead Dual GLP-1/GIP Receptor ...

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and end...

4 months ago - PRNewsWire

Viking Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference

SAN DIEGO, Jan. 3, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and en...

4 months ago - PRNewsWire

Down 24.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics, Inc. (VKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earn...

5 months ago - Zacks Investment Research

Wall Street Analysts Think Viking Therapeutics, Inc. (VKTX) Could Surge 226%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 225.8% in Viking Therapeutics, Inc. (VKTX). While the effectiveness of this highly sought-after metric is questio...

5 months ago - Zacks Investment Research

Viking Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and en...

6 months ago - PRNewsWire

Viking Therapeutics, Inc. (VKTX) Now Trades Above Golden Cross: Time to Buy?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

6 months ago - Zacks Investment Research

Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endo...

6 months ago - PRNewsWire

How Much Upside is Left in Viking Therapeutics, Inc. (VKTX)? Wall Street Analysts Think 204%

The consensus price target hints at a 204.1% upside potential for Viking Therapeutics, Inc. (VKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...

6 months ago - Zacks Investment Research

Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek® 2021

SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endo...

6 months ago - PRNewsWire

Viking Therapeutics to Report Financial Results for Third Quarter 2021 on November 3, 2021

SAN DIEGO, Oct. 27, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and e...

6 months ago - PRNewsWire

Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021

SAN DIEGO, Oct. 25, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and end...

6 months ago - PRNewsWire